Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 13, 2021

Japan approves Oncomine test as CDx with lung cancer medication

Oncomine Dx Target Test can identify specific genetic changes in tumours found in patients with non-small cell lung cancer.

Japanese regulatory agency Ministry of Health, Labour and Welfare (MHLW) has approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) with a lung cancer medication.

The Oncomine test was granted approval as a next-generation sequencing (NGS)-based CDx for patients suffering from RET-fusion positive non-small-cell lung cancer (NSCLC) who can be treated with Eli Lilly and Company’s selpercatinib (formerly known as LOXO-292).

The move comes a year after MHLW granted orphan drug designation to selpercatinib.

Thermo Fisher Scientific Japan vice-president and general manager Hiroo Murota said: “This approval will help patients suffering from NSCLC whose tumours are positive for fusions in the RET receptor, providing access to new, potentially more effective treatments.

“We will continue to advance precision medicine by expanding our companion diagnostic tests that identify biomarkers associated with targeted therapies.”

The Oncomine Dx Target Test is developed to identify different specific genetic changes in tumours found in patients with non-small cell lung cancer. The lab test also helps in determining if certain medications can help in treating cancerous growth.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Thermo Fisher currently offers the NGS-based CDx solution in more than 15 countries. In Japan, the test now has approvals for five biomarkers with a total of ten associated targeted therapies for NSCLC patients.

Headquartered in Massachusetts, US, Thermo Fisher Scientific focuses on supporting life sciences research, enhancing patient diagnostics and therapies among others.

Recently, the company’s clinical sequencing unit partnered with AstraZeneca to create NGS-based companion diagnostics.


Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy